TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05976295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive a placebo treatment.
Study: NCT05905172
Drug: The placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
Study: NCT06353165
Drug: Colgate Dental Cream
Normalized name: Colgate Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: product containing 0.76% sodium monofluorophosphate
Study: NCT05118750
Drug: ALTO-300 oral (PO) tablet
Normalized name: Altoprev Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet daily
Study: NCT05017168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching CT-P63
Study: NCT05853341
Drug: RID-TDS 13.3 mg/24 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Study: NCT05853341
Drug: Exelon® 13.3 mg/24 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Study: NCT06166056
Drug: CHF6333
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6333 Part I SAD; CHF6333 Part II MD.
Study: NCT06166056
Drug: CHF6333 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Part I SAD; Placebo Part II MD.
Study: NCT05036174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to diphenhydramine 5% ointment
Study: NCT04839510
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT00000895
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04838496
Drug: FOLFOXIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age.
Study: NCT05208242
Drug: hyperoncotic human albumin solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% human albumin solution (presented in 100ml glass bottles)
Study: NCT05208242
Drug: Buffered crystalloid solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered crystalloids solutions for all intravenous fluid therapy
Study: NCT06676384
Drug: Oral prednisolone and SoC
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.5 mg/kg per day (maximum, 40 mg/day) for two months, followed by dose tapering by 5mg per day each month for six to nine months. All participants in this arm will receive SoC and oral cotrimoxazole prophylaxis.
Study: NCT06676384
Drug: Mycophenolate mofetil (MMF) and SoC
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months). All participants in this arm will receive SoC.
Study: NCT06676384
Drug: Non-steroidal mineralocorticoid receptor antagonist and SoC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic drug not available currently. All participants in this arm will receive SoC.
Study: NCT05738135
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 50 ml normal saline over 30 minutes.
Study: NCT06081049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT05598580
Drug: Adenosylmethionine
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
Study: NCT05103423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple IV infusions of Placebo Injection diluted in sodium chloride
Study: NCT05626166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets twice daily
Study: NCT04222257
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
Study: NCT04222257
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
Study: NCT06276998
Drug: LNK01001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT06276998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT05222087
Drug: SoC systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
Study: NCT04960644
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
Study: NCT04360681
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05912387
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20 mg tablet once daily by mouth
Study: NCT00005920
Drug: L-743,872
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04784897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion
Study: NCT04784897
Drug: Standard of Care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC therapies for COVID-19
Study: NCT06143358
Drug: Qingkepingchuan Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkepingchuan Granules,Take it three times a day with water after meals.
Study: NCT06417268
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Study: NCT06417268
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Study: NCT05051527
Drug: Legalon® 140 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
Study: NCT05520086
Drug: Single Dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
Study: NCT05520086
Drug: Double Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
Study: NCT04989660
Drug: 6% aqueous phenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
Study: NCT04989660
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
Study: NCT04300985
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
Study: NCT05815797
Drug: SDD formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD formula consists of 23 herbal medicines
Study: NCT05815797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05637567
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg per os once daily
Study: NCT05637567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill per os once daily
Study: NCT04836806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
Study: NCT02021474
Drug: AGX-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT02021474
Drug: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05089526
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Study: NCT05467319
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 0.9% normal saline (w/v) by intravenous infusion
Study: NCT05981157
Drug: Anrotinib plus Tirelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Study: NCT02930811
Drug: Placebo oral morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months
Study: NCT06488625
Drug: 0 g/d CICR-NAM (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blinded)
Study: NCT04504708
Drug: ZX-101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
Study: NCT05161429
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
Study: NCT05161429
Drug: SU
Normalized name: SUMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
Study: NCT04839328
Drug: 60mg Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay005 is a small molecule PDE4 inhibitor.
Study: NCT04839328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos are the same as drugs, but contain no Hemay005.
Study: NCT06205121
Drug: OATD-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
Study: NCT06205121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT06371326
Drug: ZT002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ZT002 by subcutaneous (SC) injection.
Study: NCT06371326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo by subcutaneous (SC) injection.
Study: NCT04773678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous (SC) injection.
Study: NCT06181526
Drug: Aleeto
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.
Study: NCT05510089
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: D6: 6mg
Study: NCT05251714
Drug: CFI-402257
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral once daily in 28 day cycles
Study: NCT06304103
Drug: AND017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer AND017 once per day (QD)
Study: NCT06345716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
Study: NCT04515004
Drug: leucoselect phytosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized grape seed procyanidin extract complexed with soy phospholipid.
Study: NCT06532643
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
Study: NCT04773964
Drug: MET642
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET642 active treatment
Study: NCT04773964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT06676644
Drug: non-adjuvanted
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
Study: NCT05520658
Drug: 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
Study: NCT06468098
Drug: IBI363 + Investigator's Choice SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, patients will receive IBI363 and Investigator's Choice SOC
Study: NCT06409299
Drug: Azithromycin 40 MG/ML
Normalized name: azithromycin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Antibiotic treatment
Study: NCT04976309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT05511766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: not containing drugs
Study: NCT06186622
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06186622
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT06186622
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06118827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, orally for 7 days
Study: NCT05531708
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
Study: NCT05079126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV Bolus
Study: NCT06490991
Drug: HRS-5965 tablets；HRS-5965 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
Study: NCT04427904
Drug: Bupivacaine 0.5% with 1:200 000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Study: NCT04427904
Drug: Lidocaine 2% with 1:100 000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Study: NCT06186895
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
Study: NCT01168375
Drug: conventional therapy plus umbilical cord serum eye drop
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
Study: NCT01168375
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
Study: NCT04857606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo administered as a subcutaneous injection.
Study: NCT05951309
Drug: inofolic combi
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in this group were given inofolic combi once a day for 12-16 weeks
Study: NCT05953103
Drug: Synbixin/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbixin/Placebo
Study: NCT05757388
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administers after induction of anesthesia.
Study: NCT04728724
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines.
Study: NCT05399069
Drug: VGR-R01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene Replacement Therapy
Study: NCT04820361
Drug: Cannabis sativa L., folium cum flore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Relaxation
Study: NCT04820361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Relaxation
Study: NCT05323136
Drug: MT1002 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
Study: NCT05355298
Drug: AMP945 RP2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
Study: NCT06514222
Drug: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
Study: NCT06514222
Drug: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
Study: NCT06160232
Drug: Active placebo (low dose of psilocybin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-assisted therapy
Study: NCT05077800
Drug: FOLFIRNINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion
Study: NCT06289933
Drug: BR3005
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT06289933
Drug: BR3005-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT06289933
Drug: BR3005-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT04874350
Drug: LPCN 1148
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
Study: NCT04874350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo capsule
Study: NCT04771351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT04921943
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
Study: NCT04921943
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care
Study: NCT05800041
Drug: WTX221
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
Study: NCT04730765
Drug: antibiotic therapy (medical Control Group)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatement for 10 days by oral or intravenous administration